Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03487666 · ClinicalTrials.gov registry record · Phase 2
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03487666 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 45 participants.
The verdict
NCT03487666, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective neoadjuvant chemotherapy.
Interventions
- DRUG Capecitabine
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03487666
The ClinicalTrials.gov registry entry for NCT03487666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT03487666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03487666 about?
NCT03487666 is a clinical study titled "OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease". This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective neoadjuvant chemotherapy.
What is the current status of trial NCT03487666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2018-05-21. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT03487666?
The interventions under investigation include: Capecitabine (DRUG), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03487666?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.